Georgetown University
Welcome,         Profile    Billing    Logout  
 83 Trials 
88 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Atkins, Michael B
HCRN GU16-260, NCT03117309: Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Checkmark From HCRN GU16-260 study in combination with Yervoy for advanced RCC
May 2020 - May 2020: From HCRN GU16-260 study in combination with Yervoy for advanced RCC
Checkmark From HCRN GU16-260 study in combination with Opdivo for advanced RCC
May 2020 - May 2020: From HCRN GU16-260 study in combination with Opdivo for advanced RCC
Active, not recruiting
2
164
US
Nivolumab 240 mg, OPDIVO, Ipilimumab 1mg/kg, Yervoy, Nivolumab 3mg/kg, Nivolumab 360mg
Michael B. Atkins, MD, Bristol-Myers Squibb, Hoosier Cancer Research Network
Advanced Renal Cell Carcinoma
03/22
09/23
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
174
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
02/28
02/28
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
Marshall, John L
MRD-GI, NCT05482516: Evaluating Novel Therapies in ctDNA Positive GI Cancers

Recruiting
3
20
US
Atezolizumab, TECENTRIQ, Bevacizumab, Avastin
Georgetown University, Genentech, Inc., Natera, Inc.
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
12/26
12/28
NanoCOAT, NCT04717024: The Nanowear Wearable Covid-19 Observational and Analysis Trend

Recruiting
N/A
100
US
Observational Study - no intervention
Nanowear Inc.
Covid19
12/23
12/23
SODA-SWAP, NCT06427915: Studying Glucose and Appetite Response With Alternatives to Soda Pop

Completed
N/A
30
US
OLIPOP prebiotic soda, Traditional sugar-sweetened cola
Olipop, PBC, BioFortis
Healthy Nutrition
06/24
06/24
NCT05473702: Smart Textile Sensor System for Health Monitoring

Recruiting
N/A
200
US
Nanowear SimpleSense Wearable monitoring device
Nanowear Inc.
Heart Disease Chronic, Pulmonary Disease, Chronic Obstructive, Blood Pressure, Heart Rhythm Disorder
06/24
06/24
Kessler, Craig
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
NCT05904210: Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®

Completed
N/A
17
US
SEVENFACT®
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
05/24
05/24
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Steen, Virginia D
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
05/27
07/27
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
Anderson, Karen O
PIVOT-HD, NCT05358717 / 2021-003852-18: A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

Active, not recruiting
2
252
Europe, Canada, US, RoW
PTC518, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Huntington Disease
02/25
08/25
Liu, Stephen
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
01/27
03/28
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
NCT06157892: A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Recruiting
2
172
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
07/29
07/29
NCT04499053: Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Recruiting
2
18
US
Durvalumab, Tremelimumab
Georgetown University, AstraZeneca
Carcinoma, Non-Small Cell Lung
02/27
12/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
EP0031-101, NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US, RoW
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
STK-012-101, NCT05098132: STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Recruiting
1
202
US
STK-012, pembrolizumab, pemetrexed, carboplatin
Synthekine
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
10/27
10/27
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Pishvaian, Michael J
TIGeR-PaC, NCT03257033 / 2019-002288-84: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting
3
190
Europe, US
Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath
RenovoRx, RenovoRx
Locally Advanced Pancreatic Cancer
06/26
09/26
NCT02249949: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

Completed
2
15
US
efatutazone
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Daiichi Sankyo
Liposarcoma
10/18
05/23
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT03376659: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Checkmark Study of CV301 + durvalumab in CRC & pancreatic cancer
Nov 2018 - Nov 2018: Study of CV301 + durvalumab in CRC & pancreatic cancer
Terminated
1/2
8
US
Durvalumab, MEDI4736, CV301, Capecitabine, Xeloda, Bevacizumab, Avastin
Georgetown University, Mayo Clinic, Indiana University, Emory University, National Cancer Institute (NCI), George Mason University, Thomas Jefferson University, MedImmune LLC, Bavarian Nordic
Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
08/21
08/23
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1/2
109
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
10/24
10/24
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

Recruiting
1/2
30
US
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
SignPath Pharma, Inc., Avance Clinical Pty Ltd.
Glioblastoma
02/26
05/27
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
540
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Terminated
1
23
US
Niraparib, MK-4827, Carboplatin, Paraplatin
Georgetown University, Tesaro, Inc., Oregon Health and Science University
Solid Tumor, Adult, Homologous Recombination Deficiency
10/23
10/23
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28
NCT05868629: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Recruiting
N/A
40
US
Non-investigational
Novartis Pharmaceuticals
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
05/28
05/28
Gibney, Geoffrey
NCT04091750: Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Active, not recruiting
2
14
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Cabozantinib, Cabometyx
Georgetown University, MedStar Franklin Square Medical Center, Hackensack Meridian Health, Exelixis
Melanoma
08/23
12/25
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
Wang, Judy H
Consortium-IO, NCT04208958: Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Completed
1/2
56
US
VE800, Nivolumab, Opdivo, Vancomycin Oral Capsule, Vancocin
Vedanta Biosciences, Inc., Bristol-Myers Squibb
Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
08/21
02/23
NCT04622774 / 2021-002264-41: First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

Completed
1/2
56
Europe, US
IMGC936
ImmunoGen, Inc., MacroGenics
Advanced Solid Tumor
12/23
12/23
BT5528-100, NCT04180371 / 2019-003653-29: Study in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Recruiting
1/2
288
Europe, US, RoW
BT5528, Nivolumab, Opdivo
BicycleTx Limited
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
10/25
10/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT05887492: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Recruiting
1/2
126
US
TNG260, Pembrolizumab, Keytruda
Tango Therapeutics, Inc.
Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
01/26
06/26
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
DB-1310-O-1001, NCT05785741: A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting
1/2
1000
US, RoW
DB-1310, Trastuzumab, Osimertinib
DualityBio Inc.
Advanced Solid Tumor
08/26
08/26
EP0031-101, NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US, RoW
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
NCT05821777: A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors

Active, not recruiting
1/2
25
Europe, US
LB101
Centessa Pharmaceuticals (UK) Limited, LockBody Therapeutics Ltd
Advanced Solid Tumor
10/25
01/27
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 As Monotherapy and Combination Therapy in Subjects with BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT03518554: A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Completed
1
38
US
JAB-3068
Jacobio Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
02/22
02/22
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Terminated
1
118
US
MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
BioNTech Research & Development, Inc.
Pancreatic Cancer
08/24
01/25
CTX-8371-001, NCT06150664: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Recruiting
1
55
US
CTX-8371
Compass Therapeutics
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
10/25
04/26
BTX-A51-002, NCT04872166: A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Recruiting
1
112
US
BTX-A51
Edgewood Oncology Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
05/26
05/27
IMGN151-1001, NCT05527184: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Recruiting
1
423
US
IMGN151
AbbVie
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
02/27
02/27
NCT06075810: A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Recruiting
1
48
US
MBQ-167, Rac and Cdc42 inhibitor, Rac inhibitor, Cdc42 inhibitor, PAK inhibitor, Rac/Cdc42 inhibitor
MBQ Pharma, Congressionally Directed Medical Research Programs
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
10/25
10/25
NCT06667141: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Recruiting
1
90
US
ACR-2316
Acrivon Therapeutics
Specific Advanced Solid Tumors
08/26
12/26
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
KEYNOTE-D44, NCT04609579: Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Terminated
1
27
US
SNX281, pembrolizumab, KEYTRUDA®
Stingthera, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Lymphoma
01/24
01/24
Turner, Raymond S
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
800
Europe, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
04/24
03/26
NCT06677203: Study of ASN51 in Adults With Early Alzheimer's Disease

Terminated
2
123
US
ASN51, Placebo
Asceneuron S.A.
Alzheimer Disease
11/24
11/24
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting
2
359
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
11/26
11/26
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
MIRROR, NCT04494295: The Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation

Recruiting
N/A
500
US
Aurora Surgiscope System
Integra LifeSciences Corporation, Icahn School of Medicine at Mount Sinai, Oculus Imaging LLC
Supratentorial Hemorrhage
10/28
10/29
Salem, Mohamed
NCT06032195: Study of Organ Perfusion in Heart Transplantation in Children

Recruiting
2
15
Europe
Custodiol-N, Solution for organ preservation in transplantation, Custodiol
Dr. F. Köhler Chemie GmbH
Heart Transplantation
04/25
12/25
MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting
N/A
750
Canada, US
MRD
Exact Sciences Corporation, NSABP Foundation Inc
Colorectal Cancer
02/28
02/28
Smith, Coleman
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36
Willey, Shawna C
NCT01570998: Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Active, not recruiting
N/A
1259
US
Intraoperative Radiation Therapy, Intraoperative Radiotherapy, IORT, radiotherapy, intraoperative, Laboratory Biomarker Analysis
University of California, San Francisco, Carl Zeiss Meditec AG
Stage IA Breast Cancer, Stage IIA Breast Cancer
12/28
12/28
Cramer, Gayle
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
MK-3475-A70, NCT04865887: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Recruiting
2
35
US
Pembrolizumab, Lenvatinib
Georgetown University, Merck Sharp & Dohme LLC
Cervical Cancer, Metastatic Cervical Cancer
07/25
07/25
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
Zhang, Jialing
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
248
Canada, US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation
12/26
12/28
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
AFNT211-22-101, NCT06105021: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Recruiting
1/2
100
US
AFNT-211
Affini-T Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
12/25
12/29
XTX301-01, NCT05684965: XTX301 in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US
XTX301
Xilio Development, Inc.
Advanced Solid Tumor
02/27
02/27
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
STK-012-101, NCT05098132: STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Recruiting
1
202
US
STK-012, pembrolizumab, pemetrexed, carboplatin
Synthekine
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
10/27
10/27
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
840
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
NCT06116110: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Not yet recruiting
N/A
150
US
Long-term Follow-Up
Miltenyi Biomedicine GmbH
Non Hodgkin Lymphoma
12/39
12/39
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Atkins, Michael B
HCRN GU16-260, NCT03117309: Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Checkmark From HCRN GU16-260 study in combination with Yervoy for advanced RCC
May 2020 - May 2020: From HCRN GU16-260 study in combination with Yervoy for advanced RCC
Checkmark From HCRN GU16-260 study in combination with Opdivo for advanced RCC
May 2020 - May 2020: From HCRN GU16-260 study in combination with Opdivo for advanced RCC
Active, not recruiting
2
164
US
Nivolumab 240 mg, OPDIVO, Ipilimumab 1mg/kg, Yervoy, Nivolumab 3mg/kg, Nivolumab 360mg
Michael B. Atkins, MD, Bristol-Myers Squibb, Hoosier Cancer Research Network
Advanced Renal Cell Carcinoma
03/22
09/23
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Active, not recruiting
2
174
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
02/28
02/28
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
Marshall, John L
MRD-GI, NCT05482516: Evaluating Novel Therapies in ctDNA Positive GI Cancers

Recruiting
3
20
US
Atezolizumab, TECENTRIQ, Bevacizumab, Avastin
Georgetown University, Genentech, Inc., Natera, Inc.
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
12/26
12/28
NanoCOAT, NCT04717024: The Nanowear Wearable Covid-19 Observational and Analysis Trend

Recruiting
N/A
100
US
Observational Study - no intervention
Nanowear Inc.
Covid19
12/23
12/23
SODA-SWAP, NCT06427915: Studying Glucose and Appetite Response With Alternatives to Soda Pop

Completed
N/A
30
US
OLIPOP prebiotic soda, Traditional sugar-sweetened cola
Olipop, PBC, BioFortis
Healthy Nutrition
06/24
06/24
NCT05473702: Smart Textile Sensor System for Health Monitoring

Recruiting
N/A
200
US
Nanowear SimpleSense Wearable monitoring device
Nanowear Inc.
Heart Disease Chronic, Pulmonary Disease, Chronic Obstructive, Blood Pressure, Heart Rhythm Disorder
06/24
06/24
Kessler, Craig
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
NCT05904210: Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®

Completed
N/A
17
US
SEVENFACT®
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
05/24
05/24
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Steen, Virginia D
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
05/27
07/27
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
Anderson, Karen O
PIVOT-HD, NCT05358717 / 2021-003852-18: A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

Active, not recruiting
2
252
Europe, Canada, US, RoW
PTC518, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Huntington Disease
02/25
08/25
Liu, Stephen
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
01/27
03/28
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
NCT06157892: A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Recruiting
2
172
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
07/29
07/29
NCT04499053: Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Recruiting
2
18
US
Durvalumab, Tremelimumab
Georgetown University, AstraZeneca
Carcinoma, Non-Small Cell Lung
02/27
12/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
EP0031-101, NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US, RoW
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
STK-012-101, NCT05098132: STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Recruiting
1
202
US
STK-012, pembrolizumab, pemetrexed, carboplatin
Synthekine
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
10/27
10/27
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Pishvaian, Michael J
TIGeR-PaC, NCT03257033 / 2019-002288-84: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting
3
190
Europe, US
Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath
RenovoRx, RenovoRx
Locally Advanced Pancreatic Cancer
06/26
09/26
NCT02249949: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

Completed
2
15
US
efatutazone
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Daiichi Sankyo
Liposarcoma
10/18
05/23
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT03376659: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Checkmark Study of CV301 + durvalumab in CRC & pancreatic cancer
Nov 2018 - Nov 2018: Study of CV301 + durvalumab in CRC & pancreatic cancer
Terminated
1/2
8
US
Durvalumab, MEDI4736, CV301, Capecitabine, Xeloda, Bevacizumab, Avastin
Georgetown University, Mayo Clinic, Indiana University, Emory University, National Cancer Institute (NCI), George Mason University, Thomas Jefferson University, MedImmune LLC, Bavarian Nordic
Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
08/21
08/23
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1/2
109
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
10/24
10/24
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

Recruiting
1/2
30
US
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
SignPath Pharma, Inc., Avance Clinical Pty Ltd.
Glioblastoma
02/26
05/27
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
540
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
NCT03209401: Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Terminated
1
23
US
Niraparib, MK-4827, Carboplatin, Paraplatin
Georgetown University, Tesaro, Inc., Oregon Health and Science University
Solid Tumor, Adult, Homologous Recombination Deficiency
10/23
10/23
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28
NCT05868629: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Recruiting
N/A
40
US
Non-investigational
Novartis Pharmaceuticals
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
05/28
05/28
Gibney, Geoffrey
NCT04091750: Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Active, not recruiting
2
14
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Cabozantinib, Cabometyx
Georgetown University, MedStar Franklin Square Medical Center, Hackensack Meridian Health, Exelixis
Melanoma
08/23
12/25
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
Wang, Judy H
Consortium-IO, NCT04208958: Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Completed
1/2
56
US
VE800, Nivolumab, Opdivo, Vancomycin Oral Capsule, Vancocin
Vedanta Biosciences, Inc., Bristol-Myers Squibb
Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
08/21
02/23
NCT04622774 / 2021-002264-41: First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

Completed
1/2
56
Europe, US
IMGC936
ImmunoGen, Inc., MacroGenics
Advanced Solid Tumor
12/23
12/23
BT5528-100, NCT04180371 / 2019-003653-29: Study in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Recruiting
1/2
288
Europe, US, RoW
BT5528, Nivolumab, Opdivo
BicycleTx Limited
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
10/25
10/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT05887492: Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Recruiting
1/2
126
US
TNG260, Pembrolizumab, Keytruda
Tango Therapeutics, Inc.
Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
01/26
06/26
GV20-0251-100, NCT05669430: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Recruiting
1/2
365
US
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], MK-3475
GV20 Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
12/26
09/27
DB-1310-O-1001, NCT05785741: A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting
1/2
1000
US, RoW
DB-1310, Trastuzumab, Osimertinib
DualityBio Inc.
Advanced Solid Tumor
08/26
08/26
EP0031-101, NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US, RoW
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
NCT05821777: A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors

Active, not recruiting
1/2
25
Europe, US
LB101
Centessa Pharmaceuticals (UK) Limited, LockBody Therapeutics Ltd
Advanced Solid Tumor
10/25
01/27
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 As Monotherapy and Combination Therapy in Subjects with BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT03518554: A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Completed
1
38
US
JAB-3068
Jacobio Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
02/22
02/22
MV-0715-CP-001.01, NCT02672917: Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Terminated
1
118
US
MVT-5873, HuMab-5B1, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
BioNTech Research & Development, Inc.
Pancreatic Cancer
08/24
01/25
CTX-8371-001, NCT06150664: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Recruiting
1
55
US
CTX-8371
Compass Therapeutics
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
10/25
04/26
BTX-A51-002, NCT04872166: A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Recruiting
1
112
US
BTX-A51
Edgewood Oncology Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
05/26
05/27
IMGN151-1001, NCT05527184: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Recruiting
1
423
US
IMGN151
AbbVie
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
02/27
02/27
NCT06075810: A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Recruiting
1
48
US
MBQ-167, Rac and Cdc42 inhibitor, Rac inhibitor, Cdc42 inhibitor, PAK inhibitor, Rac/Cdc42 inhibitor
MBQ Pharma, Congressionally Directed Medical Research Programs
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
10/25
10/25
NCT06667141: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Recruiting
1
90
US
ACR-2316
Acrivon Therapeutics
Specific Advanced Solid Tumors
08/26
12/26
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
KEYNOTE-D44, NCT04609579: Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Terminated
1
27
US
SNX281, pembrolizumab, KEYTRUDA®
Stingthera, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Lymphoma
01/24
01/24
Turner, Raymond S
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
800
Europe, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
04/24
03/26
NCT06677203: Study of ASN51 in Adults With Early Alzheimer's Disease

Terminated
2
123
US
ASN51, Placebo
Asceneuron S.A.
Alzheimer Disease
11/24
11/24
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting
2
359
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
11/26
11/26
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
MIRROR, NCT04494295: The Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation

Recruiting
N/A
500
US
Aurora Surgiscope System
Integra LifeSciences Corporation, Icahn School of Medicine at Mount Sinai, Oculus Imaging LLC
Supratentorial Hemorrhage
10/28
10/29
Salem, Mohamed
NCT06032195: Study of Organ Perfusion in Heart Transplantation in Children

Recruiting
2
15
Europe
Custodiol-N, Solution for organ preservation in transplantation, Custodiol
Dr. F. Köhler Chemie GmbH
Heart Transplantation
04/25
12/25
MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting
N/A
750
Canada, US
MRD
Exact Sciences Corporation, NSABP Foundation Inc
Colorectal Cancer
02/28
02/28
Smith, Coleman
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
TARGET-HCC, NCT02954094: A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Recruiting
N/A
10000
Europe, US
Target PharmaSolutions, Inc.
Hepatocellular Cancer
10/25
10/25
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting
N/A
15000
Europe, US
Target PharmaSolutions, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
07/36
07/36
Willey, Shawna C
NCT01570998: Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

Active, not recruiting
N/A
1259
US
Intraoperative Radiation Therapy, Intraoperative Radiotherapy, IORT, radiotherapy, intraoperative, Laboratory Biomarker Analysis
University of California, San Francisco, Carl Zeiss Meditec AG
Stage IA Breast Cancer, Stage IIA Breast Cancer
12/28
12/28
Cramer, Gayle
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
MK-3475-A70, NCT04865887: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Recruiting
2
35
US
Pembrolizumab, Lenvatinib
Georgetown University, Merck Sharp & Dohme LLC
Cervical Cancer, Metastatic Cervical Cancer
07/25
07/25
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
Zhang, Jialing
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
248
Canada, US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation
12/26
12/28
ARCITECT, NCT05928806: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Recruiting
2
120
US
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Ipilimumab, Yervoy, Nivolumab, Opdivo
Michael B. Atkins, MD, Agenus Inc., Georgetown University
Advanced Renal Cell Carcinoma
10/25
10/26
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
AFNT211-22-101, NCT06105021: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Recruiting
1/2
100
US
AFNT-211
Affini-T Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
12/25
12/29
XTX301-01, NCT05684965: XTX301 in Patients with Advanced Solid Tumors

Recruiting
1/2
358
US
XTX301
Xilio Development, Inc.
Advanced Solid Tumor
02/27
02/27
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
STK-012-101, NCT05098132: STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Recruiting
1
202
US
STK-012, pembrolizumab, pemetrexed, carboplatin
Synthekine
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
10/27
10/27
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
840
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
NCT06116110: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Not yet recruiting
N/A
150
US
Long-term Follow-Up
Miltenyi Biomedicine GmbH
Non Hodgkin Lymphoma
12/39
12/39

Download Options